Loading…
As of 19 Oct 2026: Citurgia Biochemicals ₹102.45 (m-cap ₹1,352 Cr) vs TGV Sraac ₹124.55 (m-cap ₹1,333 Cr, P/E 10.1). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | Citurgia Biochemicals | TGV Sraac |
|---|---|---|
| Share price | ₹102.45 | ₹124.55 |
| Day change | −0.97% | +13.90% |
| Market cap | ₹1,352 Cr | ₹1,333 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | — | 10.1 |
| P/BPrice ÷ book value per share. | — | 1.0 |
| ROEReturn on equity. | — | 10.7% |
| ROCEReturn on capital employed. | -2,149.9% | 13.1% |
| Sales growth (3Y CAGR) | — | -5.7% |
| Profit growth (3Y CAGR) | -31.7% | -28.6% |
| Debt to equity | — | 0.27 |
| Dividend yield | 0.00% | 0.81% |
| 1-year price return | — | +0.4% |
| Promoter holding | 99.4% | 64.3% |
| Industry | Commodity Chemicals | Commodity Chemicals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Citurgia Biochemicals Ltd is larger, with a market cap of ₹1,352 Cr against ₹1,333 Cr for TGV Sraac Ltd as of 19 Oct 2026 — about 1.0 times the size.
Citurgia Biochemicals Ltd has no meaningful P/E right now (a loss over the last twelve months, or no reported earnings), so the two cannot be compared on P/E.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours (delayed by up to 15 minutes) and ratios update when the companies report results. Each number is the same one shown on the two stock pages.